Business ❯ Biotechnology

Drug Development

Clinical Trials Clinical Research Artificial Intelligence Regulatory Affairs Autoimmune Diseases Patent Expiration Axovant Sciences Regulatory Environment Cancer Therapies FDA Approvals Animal Health Lifespan Extension Contract Research Organizations Regulatory Approval Translational Research Funding Regulatory Compliance Computational Models Leadership Collaborations Therapies Neuro-immunology Market Approval Antibody Discovery Therapeutics Pharmaceuticals Pharmaceutical Industry AI in Healthcare Market Performance Immunotherapy Commercial Assets Market Competition AI-Driven Solutions Autoimmune Drugs

Isomorphic Labs Raises $2.1 Billion to Scale AI Drug Design

Investors are backing a push to prove AI-designed drugs in human trials by late 2026.

Evotec Leans Into Biologics as Horizon Overhaul Sets 2026 Reset

Sarepta Reports Early siRNA Data Showing Muscle Delivery as Shares Surge

Chai Discovery Raises $130 Million Series B at $1.3 Billion Valuation

Zealand Pharma Unveils ‘Metabolic Frontier 2030’ With Targets for Five Launches

PsiThera Raises $47.5 Million and Appoints Eric Shaff as CEO to Push Oral TNF Small-Molecule Drugs

Biogen, Dayra Launch $50 Million Pact to Develop Oral Macrocyclic Peptides for Immunology

Roivant’s Brepocitinib Succeeds in 52-Week Dermatomyositis Phase 3 as Companies Target 2026 FDA Filing

NRG Therapeutics Raises £50M to Advance Mitochondrial Neurodegeneration Drug Into the Clinic

FDA Names George Tidmarsh Director of Center for Drug Evaluation and Research

Sarepta Defies FDA, Keeps Duchenne Gene Therapy on the Market